PolyPid ($PYPD): What Does a November 28 PDUFA Date Rest On at a Company Holding $6.6 Million of Cash?

01 Bull, base and bear scenarios

These are reading frames, not forecasts, and none of them is a recommendation. Each is written so that a reader can say which document would confirm or break it.

What separates PolyPid from most companies approaching a November 28, 2026 FDA goal date is that the clinical and regulatory risk has been reduced in public and documented step by step, while the financial risk is stated in the company’s own reviewed accounts and has not moved. The trial reported, the registry posted the full numbers, the agency accepted the file without identifying issues, Europe validated, and a partner paid $30 million. What has not changed is a balance sheet of $6.56 million of cash and $5.4 million of equity carrying a going-concern conclusion, a 7.33 million-share free float, a redacted share of someone else’s profits as the main economic term in the United States, and an unpartnered Europe. The two risks are not the same kind, and a reader should not let the strength of the first obscure the plainness of the second.

What Would Falsify This Reading

The reading on this page is that the clinical and regulatory risk has largely been taken down in public, that the open risks are funding, the redacted economics of the United States licence and an unpartnered Europe, and that the company’s own descriptions of its data have drifted in ways worth noticing. Each of the following would damage that reading, and each is checkable.

• The pivotal result is not a press-release claim, it is a posted registry result. SHIELD II’s results were first posted on July 13, 2026, from a 975-patient, triple-masked trial at 58 sites in 13 countries. In the 798-patient population with incisions over 20 cm the 30-day composite ran 10.9 against 18.1 per cent, a risk difference of −7.2 (95% CI −12.1, −2.3), p=0.0039; infection alone 3.8 against 9.5 per cent, p=0.0013; the composite across all 975 randomised 11.1 against 17.4 per cent, p=0.0047; severe wound scores 2.0 against 5.6 per cent, p=0.0103. The annual report records “no difference in serious treatment-emergent adverse events” between arms.
• But the population that worked was carved out of a trial that failed. SHIELD I, on 977 patients, missed its primary endpoint — 9.3 against 12.1 per cent, difference −2.8 (95% CI −6.7, +1.0), p=0.152. The 423-patient, >20 cm pre-specified subgroup the FDA had asked for showed a 54 per cent reduction, p=0.0032, and that definition became SHIELD II’s registered primary-analysis population. That is the structural fact of the programme — and SHIELD I, its missed endpoint and the subgroup rationale were removed from the FY2025 annual report altogether, after appearing in the two before it.
• The company’s own effect sizes and endpoint labels have moved without acknowledgement. The topline release of June 9, 2025 called the primary “a 38% reduction” and the key secondary “a 58% reduction”; the annual report of February 25, 2026, on identical rates, says 40 per cent and 60 per cent. The later figures are the arithmetically correct ones and no filing acknowledges the change. Separately the 60 per cent at p=0.0013 is a key secondary — the infection rate alone — not the primary, yet several releases, the October 1, 2026 validation release among them, place it beside the primary in their opening text before calling it secondary further down.
• The United States economics are redacted and Europe has no partner at all. The press release describes “tiered royalties ranging from mid-teen to mid-twenties percentages”; the filed agreement’s operative clause is headed “Product Net Profit Sharing” with the “Applicable Percentage” redacted, as are milestones three to nine and the whole of the termination provisions. Three filings give three different additional-milestone totals. In Europe the Advanz licence was terminated by mutual agreement on October 1, 2026, rights reverting to PolyPid, with no consideration disclosed either way and the $2,548 thousand of upfront money still in deferred revenue with no stated treatment after termination.
• A reader cannot check some of this the way they could at a domestic filer. PolyPid is a foreign private issuer: it files annual reports on Form 20-F and current reports on Form 6-K, not 10-K, 10-Q and 8-K. There is a March 31 balance sheet in the Q1 earnings release, alongside quarterly expense and loss figures; the full reviewed interim accounts cover six months. Q1 financial release. It files no proxy statement, so not one numerical vote tally exists for any shareholder meeting, the compensation votes included. On insiders the position is unusual: no Form 3, 4 or 5 existed before March 18, 2026, the body of the FY2025 annual report says foreign-private-issuer status exempts insiders from Section 16 while Exhibit 11.1 to the same filing dates the obligation to March 18, 2026, and Forms 3 and Forms 4 have since been filed by the directors and officers — every Form 4 transaction an option grant from the company, with no open-market purchase and no sale by any insider in the record. The regime gives less frequent and less granular insider and periodic data than a domestic filer would, and that scarcity is not evidence of absence.
• Or the balance sheet is the binding constraint and the rest is secondary. This is the strongest argument against the page. The reviewed interim notes state substantial doubt about going concern and that funding has not been raised for twelve months; the FY2025 auditor’s report concludes the same. Cash and deposits are $6,563 thousand against a half-year operating outflow of $13,835 thousand, equity is $5,388 thousand against a $2.5 million Nasdaq minimum breached once in November 2024 with no cure letter ever filed, revenue has been zero in every period, and the 7,289,644 warrants at $4.50 expire in June 2027 — in the money against the $5.37 close of October 1, 2026, and worth about $32.8 million to the company if exercised in full. The market that has to absorb any of this is small: on market-data figures as of October 2, 2026, a whole-company value of about $109.07 million, a free float of 7.33 million shares of 20.31 million outstanding, insider ownership of 63.91 per cent and institutional ownership of 17.07 per cent, on three-month average volume of 192,730 shares — so that warrant tranche is, on its own, roughly the size of the entire float. Those comparisons are calculations against a market-data aggregate, not company disclosures.

None of these is a prediction. They are the observations that would make the rest of this page wrong, listed so that a reader can check them against the filings rather than take the reading on trust.

02 Executive answer: what November 28 decides

Four facts set the frame, and the first is the only date on this page that matters.

There is a decision in front of the agency, and its PDUFA goal date is November 28, 2026. The New Drug Application for D-PLEX₁₀₀ was submitted on a rolling basis under Fast Track — opened March 31, 2026 with the chemistry-manufacturing and nonclinical modules, completed June 1, 2026 — and was accepted for filing on July 27, 2026 with Priority Review. The company’s wording on the acceptance is worth having exactly: “The FDA did not identify any filing review issues.” Priority Review, in the company’s own description, “shortens the FDA’s target review timeline from ten months to approximately six months,” which put the goal date about one quarter ahead of the first-quarter-2027 window guided in June 2026. A goal date is a date by which the agency aims to act. It is not an approval, and nothing in the record states what the agency will decide.

What the record supplies on the favourable side is one pivotal trial that met everything it was asked to meet. SHIELD II, 975 patients randomised at 58 sites in 13 countries, hit its primary endpoint in the pre-specified population of incisions longer than 20 cm: the composite of surgical-site infection, reintervention and all-cause death within 30 days ran 10.9 per cent against 18.1 per cent, a risk difference of −7.2 (95% CI −12.1, −2.3), p=0.0039. All three key secondaries followed: infection alone 3.8 against 9.5 per cent, p=0.0013; the composite across all 975 randomised 11.1 against 17.4 per cent, p=0.0047; an ASEPSIS wound score above 20 in 2.0 against 5.6 per cent, p=0.0103. One trial was always going to be enough: in May 2021 the agency agreed that “a single pivotal Phase 3 study is sufficient, provided the study results are adequate, for potential approval,” and after the December 3, 2025 pre-NDA interaction the company reported the FDA “agreed that the Company’s existing clinical data package… appears adequate to support NDA submission and review.”

What the record supplies on the other side is the trial before it. SHIELD I, 977 patients, missed the same primary endpoint: 9.3 against 12.1 per cent, a risk difference of −2.8 with a confidence interval that crossed zero (95% CI −6.7, +1.0), p=0.152. The population on which SHIELD II succeeded is the large-incision subgroup SHIELD I produced after the fact, at the agency’s own request. So the application rests on one statistically positive trial whose primary-analysis population was defined by the failure of its predecessor, plus a 202-patient Phase 2 that showed 10 against 24 events, p=0.0086. Three things a reader will look for are not in the record at all: no advisory committee has been scheduled or ruled out, no FDA pre-approval manufacturing inspection is disclosed, and no Special Protocol Assessment exists.

What the date decides commercially is the company’s first dollar of product revenue, because there has never been one. Revenue is zero in every period PolyPid has ever reported. The United States and Canadian rights went to Azurity Pharmaceuticals on July 17, 2026 for $15 million on execution plus $15 million on filing acceptance — $30 million confirmed against “up to approximately $320 million in total upfront and milestone payments” inclusive of it, with a United States launch targeted for early 2027. Europe came back to PolyPid on October 1, 2026, when it and ADVANZ PHARMA mutually agreed to terminate their 2022 agreement; the European application was validated by the EMA the same day.

03 The two SHIELD trials, and what separates them

PolyPid ran the same 30-day composite endpoint twice, in two trials of almost exactly the same size, four years apart. One failed and one succeeded, and the difference between them is a population definition. Holding the two apart is the whole trick to reading this company.

On safety, both the company statements and the posted registry results must be considered. The annual report states that SHIELD II “revealed a good safety profile with no difference in serious treatment-emergent adverse events between patients treated with D-PLEX₁₀₀ arm versus standard of care arm,” and the topline release that “there were no safety concerns raised by the independent Data Safety Monitoring Board.” The posted ClinicalTrials.gov results provide arm-level adverse-event data over 60 days. SHIELD II, first posted July 13, 2026, reports serious adverse events in 75/481 participants receiving D-PLEX plus standard of care and 85/493 receiving standard of care alone; deaths were 10/481 and 19/493. SHIELD I, first posted June 22, 2025, reports serious adverse events in 69/478 and 98/498; deaths were 16/485 and 17/489. The registry reports different SHIELD I denominators for serious events and deaths; neither matches the efficacy population. These counts do not by themselves show treatment causality, statistical superiority or equivalence of safety, and are distinct from the company’s serious treatment-emergent-event wording. SHIELD II registry; SHIELD I registry.

What the company did with the failure

The filings describe the miss flatly — the trial “did not achieve its primary endpoint of reduction in SSIs, re-interventions due to SSIs and mortality,” a decrease of 23 per cent against standard of care at p=0.1520 — and then move straight to a subgroup. Verbatim: “in a pre-specified subgroup ITT analysis requested by the FDA of a total of 423 subjects with large incisions (>20 centimeters), the local administration of D-PLEX₁₀₀ resulted in a significant reduction of 54 percent in the primary endpoint, compared to SoC alone (p=0.0032).” Within it, infections at 30 days ran 4.4 per cent on drug (n=212) against 9.7 per cent on standard of care (n=211), and a separate post hoc analysis showed a 34 per cent reduction in patients with one or more personal risk factors, p=0.047, n=680. No filing offers a mechanistic or operational explanation for why the overall population failed; the subgroup is the whole of the company’s response to it.

That subgroup then became the primary-analysis population of SHIELD II. This is the single most important structural fact in the programme: the registered SHIELD II primary endpoint is specified “in the Population of Subjects With Target Incision Length >20 cm,” while randomisation continued down to 7 cm and the all-randomised result was carried as a key secondary. The agency sanctioned the sequence. In January 2023, after SHIELD I data went in as a Type D meeting request, “the FDA acknowledged that the SHIELD I results may provide supportive evidence on this population and recommended that we conduct an additional study,” adding that the ongoing SHIELD II “could potentially serve as such a study.” In May 2023 the FDA “agreed to our SHIELD II Phase 3 trial design.”

Two gaps sit in the middle of that. The releases and the annual report both refer to “the 2023 trial protocol change” and to laparoscopic patients enrolled before it, and recruitment was “resumed… in June 2023” — but the content of that amendment is not in the record, and neither is the reason for the pause that preceded it. And SHIELD I is absent from the FY2025 annual report altogether: its “Key Completed Clinical Trials” section discusses only SHIELD II, and the missed primary endpoint and large-incision rationale that appear in the FY2023 and FY2024 reports were removed from the one filed February 25, 2026 — the report sitting closest to the application now under review.

The interim analysis, and what it did and did not say

SHIELD II carried one planned unblinded interim analysis, on the first 430 enrolled patients once they had completed 30-day follow-up. The Data Safety Monitoring Board had four options, verbatim: “early trial conclusion due to positive efficacy, continuation to planned patient recruitment (up to 630 subjects), sample size re-assessment, or futility.” Its recommendation, announced December 23, 2024, was “to conclude the study upon enrollment of 800 patients, which is the lowest sample size reassessment stop after the minimum planned number of 624 patients,” against a maximum of 1,100. So the trial was neither stopped for futility nor stopped for overwhelming efficacy, and the board “confirmed the good safety profile of D-PLEX₁₀₀ in SHIELD II to date.” The interim efficacy numbers were never disclosed.

Two consequences travelled with it. The company announced enrolment complete on the 800-patient basis in March 2025 while the registry records 975 randomised — reconcilable only through the two populations, 798 at greater than 20 cm and 975 at greater than 7 cm, a reconciliation never stated in one place. And the warrants from two private placements had been written to expire on a recommendation to stop for positive efficacy, so because that specific outcome did not occur, 1,181,191 of them expired unexercised in January 2026.

The Phase 2 underneath, and the programmes that stopped

The Breakthrough Therapy designation of November 2020 rests on a 202-patient Phase 2 in abdominal surgery, run entirely at eight Israeli sites. Counted as participants with a combined infection or death event within 30 days, the primary was 10 on D-PLEX₁₀₀ against 24 on standard of care, p=0.0086 by Fisher’s exact test, a risk ratio of 0.41, with deaths at 30 days three against zero in favour of drug.

Everything else is stopped or preclinical. The cardiac sternal Phase 3 is recorded in the registry as terminated for “company prioritization reasons” with an actual enrolment of two patients — the FY2024 report had described it as a trial in which enrolment was “paused,” to be filed as a post-approval supplement, and the FY2025 report drops it. The orthopaedic predecessor, 51 patients, showed no infections or infection-related bone morbidities at six months against 11.1 per cent on standard of care, and the company does “not plan to pursue further independent development of D-PLEX 1000.” OncoPLEX has nine animal models and a November 2021 pre-IND meeting but no IND, no trial and no registry number; the long-acting GLP-1 platform unveiled in July 2025 has no named candidate and no trial. No PolyPid trial is currently recruiting.

04 The two applications, and what each step shows

Section 3.04(a) of the July 17, 2026 Azurity agreement states that, at the agreement’s effective date, the facility was licensed by Israeli authorities for investigational medicinal products and did not have FDA or Health Canada authorization to sell products manufactured there. PolyPid is responsible for obtaining the specified manufacturer approvals. This dated contractual disclosure is distinct from Israeli audits; it does not prove a failed inspection or establish that the authorization status remained unchanged afterward. SEC filing, Exhibit 10.1.

There are two live regulatory files on D-PLEX₁₀₀, one on each side of the Atlantic, and they are at very different stages. Neither is an approval. The American one is in substantive review with a date attached; the European one was accepted as complete on October 1, 2026.

The United States: a rolling application with a goal date of November 28, 2026

PolyPid is seeking approval under section 505(b)(2) of the Food, Drug and Cosmetic Act. The application was built in instalments under its Fast Track designation: submission opened on March 31, 2026 with the chemistry-manufacturing and nonclinical modules and was completed on June 1, 2026. The rolling mechanism had been agreed in advance — written pre-NDA minutes arrived on December 3, 2025 in which, on the company’s account, “the FDA agreed that the Company’s existing clinical data package, including results from the Phase 3 SHIELD II trial, appears adequate to support NDA submission and review” and “also agreed to a rolling NDA review.” The in-person meeting scheduled for that day was cancelled as “no longer necessary.”

On July 27, 2026 the agency accepted the application for filing and granted Priority Review, and the company reported that “the FDA did not identify any filing review issues.” The PDUFA goal date is November 28, 2026. Two details give that date its shape. Priority Review, in the company’s own words, “shortens the FDA’s target review timeline from ten months to approximately six months” — which is why the goal date arrived “approximately one quarter ahead of Company’s previously communicated guidance,” the earlier guidance having been a first-quarter-2027 action date stated as recently as June 1, 2026. And acceptance for filing is a statement about the application, not about the product: it shows that the submission is complete enough to be reviewed on the merits, and it shows nothing at all about what the review will conclude. The record contains no advisory committee, scheduled or ruled out, and no disclosed FDA pre-approval inspection of the manufacturing site.

Europe: validated on October 1, 2026, which is a procedural step and no more

The European route has been in preparation for four years. In September 2022 the EMA confirmed that D-PLEX₁₀₀ was eligible for a marketing authorisation application under the Centralised Procedure on “Therapeutic Innovation” criteria, and that eligibility was reconfirmed in December 2025. In March 2023 Sweden’s medicines agency gave national scientific advice that “recommended that we confirm the results with an additional Phase 3 study to support a MAA submission and confirmed that clinical safety data obtained to date in abdominal surgery studies is sufficient for a MAA submission.” During the second quarter of 2026 the company reported “productive and positive meetings with the EMA Rapporteur and Co-Rapporteur, aligning on the timeline and requirements for the planned MAA submission.”

The application itself was submitted on September 14, 2026 and validated on October 1, 2026. The company’s description of what validation means is the one to keep: “Validation confirms that the application is complete and marks the initiation of a formal regulatory review process.” The file now enters CHMP review, by the hybrid application route. What validation is not: it is not a European approval, it is not a CHMP opinion, it carries no disclosed opinion date of any kind, and it is not the European equivalent of the American acceptance for filing — the two agencies ran separate processes on separate timetables and the November 28 date belongs only to the American one.

Europe is now unpartnered, by mutual agreement

On the same day the European application was validated, PolyPid announced the end of the agreement that was meant to sell the product there: “PolyPid and ADVANZ PHARMA have mutually agreed to terminate their 2022 exclusive License, Distribution and Supply Agreement for D-PLEX₁₀₀ in Europe. As a result, the exclusive European commercialization rights for D-PLEX₁₀₀ have reverted to PolyPid.” That is a mutual termination, not a breach by either side and not a cancellation by one of them, and what it leaves the company with is the European and United Kingdom rights back in its own hands, unpartnered.

The agreement being unwound dated from August 2, 2022, covered the European Economic Area and the United Kingdom, and was to run “until the later of December 31, 2035, or 10 years after the first commercial sale.” Its disclosed economics were a non-refundable one-time payment of €2.5 million (about $2,548 thousand), received and still carried as long-term deferred revenue at June 30, 2026 because “the Company has yet to satisfy its performance obligation,” plus development milestones of up to €23 million and commercial milestones of up to a further €87 million. No royalty rate was ever disclosed. Three things a reader should not assume: no termination payment or break fee by either party is disclosed, the accounting treatment of the $2,548 thousand after termination is not disclosed — it falls after the last reported balance-sheet date — and no replacement partner and no retained adviser is disclosed.

What the company did instead was issue an invitation, in both releases of October 1. The reversion, the chief executive said, “makes D-PLEX₁₀₀ a highly attractive opportunity for multinational pharmaceutical companies looking to enhance their product portfolio in the surgical site infection space in Europe and other large markets,” and the company sees “a meaningful opportunity to maximize the value of this asset” and is “excited by the strategic possibilities ahead.” That is an explicit solicitation for a European partner in the company’s own words. It is not a disclosed strategic review of the company: no financial adviser is named, and no takeover approach, acquisition proposal or merger agreement appears anywhere in the record.

Manufacturing, and the inspection that is not in the record

PolyPid makes the product itself, in a leased 22,000 square foot sterile facility in Petach Tikva that has been cGMP-certified by the Israeli Ministry of Health since 2019, audited in September 2023 “without any critical or major findings” and again in September 2025; those audits “are also valid for Europe under the provisions of the ACAA between the EU and Israel.” Capacity is stated as scaled to demand “for at least 48 months from product launch,” no third-party contract manufacturer is engaged, and pre-launch inventory is building, from $1,106 to $1,359 thousand over the half. No FDA pre-approval inspection of that site is disclosed in any filing.

What this issuer’s reporting regime lets a reader see

One structural point governs everything in the next section. PolyPid is an Israeli company and a foreign private issuer: it files an annual report on Form 20-F and interim and current reports on Form 6-K. That regime calls for audited annual accounts plus the interim information furnished with them, which here means semi-annual financial statements, reviewed rather than audited at the half-year, with quarterly figures appearing only in earnings releases. So the most recent balance sheet of any kind is June 30, 2026, furnished on August 12, and the third quarter of 2026 is a blank. The regime also exempts the company from the SEC proxy rules, so no numerical vote tally exists for any shareholder meeting — outcomes are narrative only, as in “the shareholders of the Company approved Proposal Nos. 1 through 4 as originally proposed.” Insider reporting did change: the company’s own insider trading policy dates Section 16 obligations to March 18, 2026, and eleven initial holdings statements were filed that spring with ten transaction reports in July 2026 — while the body of the same annual report that carries that policy as an exhibit says the opposite, that directors and senior management “are not subject to short-swing profit and insider trading reporting obligations under Section 16.” No filing explains the contradiction.

05 Six and a half million dollars, no debt, and substantial doubt

Cash, equivalents and short-term deposits fell $6,370 thousand in the first half of 2026, from $12,933 to $6,563. Over the twelve months to June 30, 2026 the fall is far larger: from $29.5 million a year earlier to $6.563 million, a decline of about $22.9 million. Equity fell $5,585 thousand over the same half, to $5.4 million, against an accumulated deficit of $317.1 million.

The burn, and the fact that it has not slowed

Operating cash use has risen in every full year on record — $17.2 million, $22.0 million, $27.9 million — and the first half of 2026 ran above the comparable half of 2025. On the quarterly figures from the earnings releases, net loss was $7.7 million in the first quarter of 2026 and $7.8 million in the second, with research and development of $5.8 and $6.1 million, so there is no deceleration in the data. One quirk belongs with the per-share line: weighted-average shares of 22,280,991 exceed the 20,311,766 actually outstanding at June 30, because the pre-funded warrants, exercisable at $0.0001 with no expiry, counted as outstanding for earnings-per-share purposes. That is not an error, but it makes per-share comparison across periods unreliable.

Debt: there is none, for the first time in four years

At June 30, 2026 PolyPid had zero interest-bearing debt. The last of it went on May 4, 2026: “the outstanding loan balance was fully repaid.” That is confirmed on the face of the balance sheet, against $988 thousand current at the end of 2025 and $6,787 thousand current plus $634 thousand long-term at the end of 2024. There is no convertible note, no promissory note, no revolver and no royalty or revenue-interest financing anywhere in the record, and no warrant is classified as a liability — every tranche is equity-classified.

The instrument that has just gone is worth a paragraph because of what it cost. A Kreos Capital secured facility of up to $15 million was signed in April 2022 in three tranches; $10 million and $2.5 million were drawn and the third tranche never was, because its milestone was not met. It was secured on owned equipment, intellectual property and the shares of both subsidiaries, and it was restructured three times, each time more expensively: the rate went from 9.25 to 10.00 per cent in 2023 and to 12.00 per cent in 2024, with 70 and then 60 per cent of remaining principal and interest deferred, restructuring fees of 1.00 per cent at close and 3.00 per cent at maturity, then $125,000 and $160,000, an end-of-loan payment raised from 5 to 7 per cent, and a warrant for 40,000 shares at $3.61. The company booked a $512 thousand loss on extinguishment and $859 thousand of fees in 2025. No financial covenant and no event of default is disclosed in any filing. What survives the repayment is 46,491 equity-classified warrants: 6,491 originally struck at $154.05 and repriced to $12.60 in 2023, plus the 40,000 at $3.61.

Every financing instrument still outstanding

Five equity transactions since the start of 2024 did all of the work, for roughly $90 million gross and no underwritten offering since the 2020 listing. Three were private placements — January 2024 at $4.81, August 2024 at $3.61, December 2024 at $3.22 — each pairing shares with pre-funded warrants and a tranche of ordinary warrants whose expiry was tied to a clinical event. That structure mattered: two of the three tranches expired worthless because the interim analysis did not stop the trial for positive efficacy, removing 1,181,191 warrants at $5.50 in January 2026 and 1,304,352 at $4.00 in June 2025. The largest raise was the June 16, 2025 inducement, which repriced 7,626,514 existing warrants to a $3.50 cash exercise in return for new warrants at $4.50, bringing in $26,690 thousand net at a $2,317 thousand modification cost booked to equity; of those new warrants, 103,950 were exercised in January 2026 for $468 thousand and 232,920 were cancelled in March 2026 “due to non-compliance with one of the terms of the Inducement Letter.” The December 2024 placement also carried a governance term: the company “agreed to consider” a partner at the subscribing fund for a board seat, and he joined the board in February 2025.

The share count, and what drove it

The count is the clearest single picture of how this has been financed. Shares outstanding went from 4,797,252 at January 31, 2024 to 10,190,904 at the end of 2024, 18,204,002 at the end of 2025 and 20,311,766 at June 30, 2026 — a 4.2-fold increase in 29 months, entirely from equity financing rather than any operating event. Adding July’s 153,140 ATM shares and 398,961 warrant-exercise shares implies about 20,863,867 after the July 2026 issuances, but that is a calculation: no share count after June 30, 2026 has been published. Authorised capital is 107,800,000 ordinary shares and has not moved. There has been exactly one reverse split, 1-for-30, effected September 18, 2023, whose residue is visible in legacy option strikes of $92.89, $117.99 and $123.01.

Stacking what exists on top of what is issued: 20,311,766 shares, 7,807,740 warrants, 3,636,777 options and 2,828,319 abeyance shares give a fully diluted figure of roughly 34.6 million, or about 36.0 million if the 1,367,427 unissued option pool is included — calculations, not disclosures. The $4.50 tranche alone would add about 35 per cent to the current count if exercised in full before June 2027.

One listing matter belongs here because the margin is thin. In November 2024 Nasdaq notified the company that it no longer met the $2,500,000 minimum stockholders’ equity requirement for the Capital Market, citing equity of approximately $2,158,000 at September 30, 2024, and gave it 45 days to file a compliance plan; the cure path described was warrant exercise. The absence of a Nasdaq compliance discussion in the 2025 annual report does not itself prove that the earlier equity deficiency was cured, and equity has since fallen back to $5,388 thousand against a $15.6 million half-year loss run-rate. The 2022 bid-price deficiency closed properly, with written notice of regained compliance on October 11, 2023 after the reverse split and no hearings panel involved.

06 The rest of the pipeline, and what is missing from it

Everything behind D-PLEX₁₀₀ in abdominal surgery is a trial that has finished, a trial that was terminated, or a slide. No PolyPid trial is currently recruiting, and no registered completion date is pending for any PolyPid trial. Every clinical result this company owns is already public and already in the past.

On October 15, 2026 PolyPid said it will introduce PD01B, a new candidate based on its Kynatrix delivery technology being developed for the treatment of diabetic foot infections, at its October 28 Investor Day; the announcement gives no development stage or timeline. Source

So the honest summary is this. There is one complete pivotal dataset that hit its primary endpoint and one that missed it, in the same indication with the same drug, and the subgroup that rescued the miss became the primary analysis population of the hit. Ahead of them sit two preclinical programmes with no IND, no trial and no registry number between them, and three completed bone studies the company has said it will not take further alone.

Three gaps are worth naming, because each is something a reader would expect to look up and cannot. The SHIELD II interim-analysis efficacy numbers were never disclosed — the analysis ran on unblinded data from the first 430 enrolled patients, and the outcome was reported only as a recommendation to “conclude the study upon enrollment of 800 patients”, with the monitoring board explicitly not stopping for futility and not stopping for overwhelming efficacy. The content of the 2023 protocol amendment is not in the record, although two filings refer to it, and the reason for the recruitment pause before June 2023 is nowhere stated. And that “800 patients” is never reconciled against the registry’s 975 randomised in one document: the reconciliation exists — 798 in the >20 cm primary population against 975 randomised at >7 cm — but the reader has to assemble it.

07 Register, insiders and short interest under a foreign-issuer regime

The Rosalind Schedule 13G/A filed August 12, 2026, with a July 31 event date, breaks the 5,124,011 reported shares into 565,655 ordinary shares and 4,558,356 shares underlying warrants. The cover-page 9.9% incorporates a blocker discussion and uses 19,174,078 shares outstanding at March 31; it is not a simple percentage of issued shares owned outright. The four reporting persons report the same shared position, which is not cumulative. SEC filing.

The regime first, because it decides what the rest of this section can say

PolyPid is a foreign private issuer. It files 20-F annual reports and 6-K current reports — six 20-Fs and 117 6-Ks on the record — and says so in its own words: “We are a foreign private issuer as defined by the rules under the Securities Act and the Exchange Act.” It is also a semi-annual reporter, so reviewed statements exist for half-years and full years only and the additional quarterly figures, including the Q1 balance sheet, come from earnings releases furnished on Form 6-K rather than a reviewed quarterly statement. Three consequences follow. The reporting frequency is half a domestic filer’s: the last reviewed balance sheet is June 30, 2026, filed August 12, 2026, so the most recent reviewed position is three months old and the next arrives with the FY2026 annual report. The lag on ownership is longer, because third-party percentage denominators may trail the issuer’s own count — and here they do, by up to four months. And the granularity on governance is absent: with no annual proxy statement and no current report carrying vote results, no numerical vote tally exists for any PolyPid shareholder meeting — no votes for, against or abstaining, no quorum size, none of the disinterested-majority counts Israeli law requires on compensation items. Outcomes are narrative only: “a quorum was present and the shareholders of the Company approved Proposal Nos. 1 through 4 as originally proposed.”

The register: every five-per-cent holder is a financing counterparty

No Schedule 13D or 13D/A has ever been filed on PolyPid — the record holds only 13G and 13G/A filings, so no activist and no control filer. What they show matters less for the percentages than for who is behind them.

Read the structural fact before the percentages: not one of the six holders above five per cent is an ordinary institutional position. Every one is a financing counterparty. Aurum is a pre-IPO and private-placement investor whose chief financial officer, Nir Dror, sits on the board — a director since May 2020 and interim chairman from August to December 2025. AIGH is a placement investor whose partner, Yitzchak Jacobovitz, sits on the board on a seat the December 23, 2024 placement release contemplated in writing: “the Company has agreed to consider Yitzchak Jacobovitz, CFA, partner and lead healthcare analyst at AIGH Capital Management, for appointment to the Company’s board of directors”; he was appointed in February 2025. Rosalind’s reported position is 87 per cent warrants; Hodges’ entities participated in the August 2024 placement; Nir and Lukach are individual placement participants. Two of the eight directors are employed by two of the four largest shareholders.

What follows is an inference, and it changes how the table reads. A large part of what the register calls ownership is warrant exposure struck at $4.50 and expiring in June 2027, held by the parties most likely to supply the next round of capital, behind 9.99 per cent blockers and an abeyance mechanism holding 2,828,319 shares unissued at June 30, 2026. Aurum’s and Hodges’ percentages are stated without caps and Rosalind’s and AIGH’s with them, so the two sets are not comparable and neither is a clean percentage of outstanding shares. The company’s own table, as of February 19, 2026 on a base of 19,083,236 shares, is the only page putting holders and insiders together: Aurum 23.81 per cent, Rosalind and AIGH 9.99 per cent capped each, Hodges 15.73 per cent, and all eleven directors and officers as a group at 688,463 shares, or 3.6 per cent.

One set of figures from outside the filings explains why the register looks like this, and they are kept separate here because the bases are not the same. Market data as of October 2, 2026 give a float of 7.33 million shares against 20.31 million outstanding, with insider ownership of 63.91 per cent and institutional ownership of 17.07 per cent. The two sides of that reconcile: 20.31 million less a 7.33 million float leaves about 12.98 million shares, which is 63.9 per cent of the count — a calculation — so the market-data source is treating the financing counterparties and affiliates in the table above as insiders. Note what that is not. The company’s own annual report puts all eleven directors and executive officers together at 688,463 shares, or 3.6 per cent. The market-data figure of 63.91 per cent and the filing’s 3.6 per cent measure different populations and neither is wrong: the filing counts the people who run the company, market data counts everything not freely trading. The consequence is the float itself. Fewer than four shares in ten are available to the market — and the ones that are not are held by six financing counterparties whose positions were last reported between two and eighteen months ago. That is the single fact that explains the shape of the 13G record above, and the 17.07 per cent institutional figure is consistent with it: the money that shows up in manager reporting is a minority of a register built out of private placements.

Insiders: eleven initial statements, ten grant reports, and not one purchase

The transaction-level record is short enough to state completely. Initial statements for eleven insiders, all event-dated March 18, 2026, set the opening positions, and across all eleven the total number of ordinary shares held outright is 4,794 — the chief executive 934, Yechezkel Barenholz 2,760, Itzhak Krinsky 833, Ori Warshavsky 267, zero for the other seven. One director, Yitzchak Jacobovitz, reported no shares and no derivative holdings at all. Everything else is unexercised options: the chief executive twelve tranches over 575,206 underlying shares at $2.67 to $117.99, the deputy chief executive 280,063, the chief financial officer 190,513, the United States chief operating officer 159,127, and the non-executive directors between 21,565 and 22,660 each.

Then the transaction reports, all filed July 17, 2026, every one transaction code “A” — an option grant from the company. Among them: the chief executive 149,000 at $4.46 dated July 15, 2026 and vesting quarterly to May 11, 2030; six non-executive directors 9,132 each at $4.46, 54,792 in total; and three officers on grants dated May 11, 2026 — Hazan 75,000, Missulawin 49,000, Warshavsky 46,000, all at $4.46. That produces the cleanest statement in this section: there is no open-market purchase by any insider in the record. None at all. No code “P” purchase, no “S” sale, no “M” exercise, no “F” tax withholding, no “G” gift. No individual Rule 10b5-1 plan is disclosed for anyone, and no restricted stock unit is outstanding anywhere in the record — the “PSUs” of the earnings releases are performance-based options that vested on the SHIELD II topline. Two things sit on top: three of those reports were filed 67 days late, the May 11 grants being reported on July 17 against a two-business-day deadline, and the group figure is almost pure optionality — of the 688,463 shares the eleven hold beneficially, 683,669, or 99.3 per cent, is unexercised options. For the earlier period the only figures are from February 19, 2026: the chief executive 305,053, Hazan 144,689, Missulawin 99,260, Warshavsky 82,486, every director under one per cent.

Management and board, as the annual report gives them

The annual report lists four executive officers, all long-tenured and with no turnover since 2023. Dikla Czaczkes Akselbrad, 52, chief executive since July 2022, previously the company’s own chief financial officer from December 2016 and before that chief financial officer of Compugen. Dalit Fellous Hazan, 55, deputy chief executive since June 2024, running research, clinical and regulatory affairs, formerly head of global regulatory affairs at Teva. Ori Warshavsky, 48, chief operating officer for the United States since January 2022. Jonny Missulawin, 39, chief financial officer since May 2023.

What is not on the list matters more. There is no chief medical officer, no chief scientific officer, no chief commercial officer and no chief business officer among the executive officers of a company with a November 28, 2026 decision date and a stated launch target in the first quarter of 2027. The medical seat has a history: Dr. Nurit Tweezer-Zaks was announced as chief medical officer on August 12, 2025, and she does not appear in the officer table of the report filed February 25, 2026, where she is named only in the past tense as a former director “paid through August 2025.” No filing addresses whether she still holds the role. Her current status is not in the record, and no Form 3 was filed for her in March 2026.

The board has eight members against articles permitting five to eleven, and seven of the eight are independent under Nasdaq rules. Brooke Story, 54, has been chairman since December 2025; she leads BD’s separation and integration management office, was worldwide president of its surgery business, and sits on the LivaNova board. The rest are Yechezkel Barenholz (April 2008, a major inventor of Doxil), Joseph BenAmram (May 2023, ex-Merck), Nir Dror (May 2020, Aurum), Yitzchak Jacobovitz (February 2025, AIGH), Itzhak Krinsky (January 2019, the designated audit committee financial expert), Robert B. Stein (around June 2020) and the chief executive. The company follows Israeli Companies Law rather than Nasdaq rules on nominations and executive compensation and appoints no Israeli external directors. The chairmanship turned over twice in six months and the first leg was never announced: Jacob Harel departed as chairman in June 2025 with no 6-K, surfacing only as Proposal No. 7 at the June 25, 2025 meeting — vesting acceleration “upon termination of services of Mr. Jacob Harel” — and a compensation footnote recording payment through June 2025. Neither the reason, the effective date nor the value of that acceleration is disclosed. Headcount was 69 full-time and 6 part-time at December 31, 2025, up 21 per cent on the year; no figure after that date is in the record, and no restructuring, workforce reduction or charge is disclosed in any filing.

No litigation, and the filing language that says so

This is worth stating directly because it is uncommon in this cohort. The filings disclose no legal proceedings at all. Verbatim, FY2025 annual report, Item 8.A: “Legal Proceedings — We are not currently subject to any material legal proceedings.” The FY2024 report is identical. No securities class action has ever been filed or disclosed, including after the September 2022 announcement that SHIELD I had missed. No derivative suit, no litigation reserve and no legal accrual in any period; the commitments-and-contingencies note contains only the Israel Innovation Authority royalty commitment. No regulatory enforcement action, SEC investigation or Nasdaq disciplinary proceeding is in the record, and no material weakness is disclosed.

The short position is small, and it collapsed after the July news

The series is small in absolute terms and small against the count. The twelve-month peak of 412,853 shares at the July 31, 2026 settlement is about 2.0 per cent of the 20,311,766 shares outstanding — a calculation — and the latest reading of 130,353 is about 0.64 per cent. Against the float rather than the count it is larger and still small: market data as of October 2, 2026 put short interest at 1.78 per cent of a 7.33 million float, which is about 130,500 shares and consistent with the exchange figure for September 15. Days to cover never exceeded 1.91 across twenty-three settlement dates and sat at the 1.00 floor in sixteen of them. The peak lines up exactly with the news cluster — the Azurity agreement announced July 21, then NDA acceptance and Priority Review granted July 27 and announced July 29 — alongside the highest average daily volume in the series, and short interest then fell 68 per cent over the following six weeks. The reading, and it is a reading, is that the short side is not where the risk sits on this name: 0.64 per cent of the count, 1.78 per cent of the float, 1.11 days to cover. What is unusual about this register is not the short position but the 7.33 million float underneath it. The latest settlement published is September 15, 2026, seventeen calendar days ago; publication runs about eight business days after settlement, so the September 30 figure is due around October 9, 2026 and is not yet in the record.

Analyst coverage

One consensus figure is worth printing with its provenance attached. Market data as of October 2, 2026 show a consensus price target of $11.75 against the $5.37 close of October 1, 2026, with the same source giving a market value of $109.07 million, 20.31 million shares outstanding against a float of 7.33 million, insider ownership of 63.91 per cent, institutional ownership of 17.07 per cent, short interest at 1.78 per cent of float and three-month average volume of 192,730 against a session volume of 118,780 — the short figure being the one that matches the exchange series, since 1.78 per cent of a 7.33 million float is about 130,500 shares against the 130,353 published for the September 15 settlement, a calculation that corroborates the float figure. The consensus is shown as a market-data aggregate, labelled as such, and none of the analysis relies on it.

08 Catalyst map, red flags and the Merlintrader bottom line

The catalyst map

One date dominates the whole record, and everything else on the map is either behind it or waiting on it.

Both branches of November 28 are worth stating flatly, because the file reads very differently on each side of them and nothing in the record predicts which it will be. On an approval, D-PLEX₁₀₀ becomes the first product this company has ever had cleared anywhere; the partner has a stated United States launch target of early 2027, PolyPid supplies product from its own facility at a transfer price and retains worldwide manufacturing rights, and the redacted regulatory and sales milestones inside the “up to approximately $320 million” total begin to come into play. On a complete response letter or any other non-approval, the company stands on a market value of $109.07 million at the October 1, 2026 close, $6,563 thousand of cash at its last reported balance-sheet date, substantial-doubt language in its most recent interim notes, no revenue in any period in its history, and a warrant block struck at $4.50 that expires in June 2027 — with the European application the only live regulatory file and, since October 1, no commercial partner attached to it. Two ordinary features of an approval path are not visible either way: no advisory committee has been scheduled or ruled out, and no pre-approval inspection of the single sterile manufacturing site is disclosed.

Red flags

• Substantial doubt about the ability to continue as a going concern is stated in the auditor’s report, in the FY2025 notes and in the most recent interim notes: “the Company has not raised the necessary funding in order to continue its activity for a period of at least one year.”
• Three different runway answers on one day. On August 12, 2026 the press release said funding “into 2028”, the management discussion said “at least twelve months” including the $15.0 million milestone, and the interim notes said the funding had not been raised. The chief executive described “no immediate financing needs.”
• Cash is thin against the burn. $6,563 thousand at June 30, 2026 against $13,835 thousand of operating cash use in that half-year; equity $5,388 thousand; accumulated deficit $317,077 thousand. Cash plus deposits fell about $22.9 million in twelve months.
• The tradeable share count going into a binary date is small. Market data as of October 2, 2026 give a float of 7.33 million shares out of 20.31 million outstanding — insider ownership of 63.91 per cent — on three-month average volume of 192,730 and a session volume of 118,780 on October 1, with the close at $5.37 and a market value of $109.07 million. The FDA decision date is November 28, 2026. Those are the figures; this page draws no conclusion from them about how the shares will trade.
• The $4.50 warrant block is now in the money. 7,289,644 warrants against a $5.37 close, expiring June 2027: full exercise is about $32.8 million of proceeds and about 35.9 per cent added to the 20,311,766 count, both calculations — and the holders are largely the same financing counterparties who hold the register.
• The disclosure regime is itself a red flag, and it is the one most readers miss. As a foreign private issuer PolyPid publishes full reviewed interim accounts semi-annually and additional unaudited quarterly figures in releases: the last reviewed balance sheet is June 30, 2026 and the next comes with the FY2026 annual report, so no further reviewed interim financial statement is scheduled before the binary decision date. With no DEF 14A proxy statement (meeting materials are furnished on Form 6-K) and no report carrying numerical vote results, no numerical vote tally exists for any shareholder meeting in the company’s history, including compensation items that require a special majority under Israeli law. And for eleven of the last eighteen months, to March 17, 2026, no transaction-level insider record existed — holdings for that window appear only as one annual snapshot dated February 19, 2026. Ownership percentages lag too: an amendment filed August 12, 2026 computes its percentage on a March 31, 2026 share count, on the day the issuer reported a higher one.
• One filing contradicts itself on whether insiders report at all. An exhibit to the FY2025 annual report dates Section 16 obligations to March 18, 2026; the body of the same report says management “are not subject to short-swing profit and insider trading reporting obligations under Section 16.” No filing explains it.
• The European partner is gone. The 2022 ADVANZ PHARMA agreement was terminated by mutual agreement on October 1, 2026 and “the exclusive European commercialization rights for D-PLEX₁₀₀ have reverted to PolyPid.” What that removes is specific: a counterparty for the EEA and the United Kingdom, up to €23 million of development milestones, up to a further €87 million of commercial milestones, and post-authorisation minimum sales requirements. No termination consideration or break fee is disclosed either way, the €2.5 million upfront is still carried as $2,548 thousand of deferred revenue on an unsatisfied performance obligation, and the treatment of that balance after termination is not in the record. Europe is unpartnered two weeks after the application was filed there.
• The predecessor pivotal missed its primary endpoint — 9.3 per cent against 12.1 per cent, p=0.152 — and SHIELD I is entirely absent from the FY2025 annual report, along with the >20 cm subgroup rationale behind the trial now under review.
• The company restated its own effect sizes without saying so, from “a 38% reduction” and “a 58% reduction” in June 2025 to 40 and 60 per cent since March 2026, on identical underlying rates. No filing acknowledges the change.
• Endpoint attribution is inconsistent inside single press releases. The 60 per cent / p=0.0013 figure is a key secondary endpoint, not the primary; the October 1, 2026 release puts it beside the primary in one paragraph and calls it “at the secondary end point” four paragraphs later.
• A Phase 3 described by the company as having enrolment “paused” is recorded by the registry as terminated for “company prioritization reasons”, with two patients enrolled. The FY2025 report drops it entirely.
• The partner economics in the press releases are not the economics in the filed agreement. The releases describe “tiered royalties ranging from mid-teen to mid-twenties percentages”; the operative clause is headed “Product Net Profit Sharing” and the Applicable Percentage is redacted, as are milestones (iii) to (ix); the full termination conditions are only partly disclosed. Milestone totals also disagree across three filings: “up to approximately $300 million in additional”, “over $290,000” thousand, and “up to approximately $320 million in total … inclusive of the $30 million.”
• Dilution has been continuous and heavy. From 4,797,252 shares at January 31, 2024 to 20,311,766 at June 30, 2026 — 4.2 times in twenty-nine months, all from equity financing, after a 1-for-30 reverse split in September 2023. Fully diluted, about 35.95 million.
• Every holder above five per cent is a financing counterparty, and two of the eight directors are employees of two of the four largest. The December 2024 placement tied a board seat to the financing in writing.
• There is no open-market purchase by any insider anywhere in the record. Every reported insider transaction is a company option grant; the eleven insiders hold 4,794 ordinary shares outright in total, and 99.3 per cent of the 688,463-share group figure is unexercised options. Three grant reports were filed 67 days after the transaction date.
• The senior team is thin for a company one month from a decision and one quarter from a stated launch. No chief medical, commercial, scientific or business officer appears in the officer table; a chief medical officer announced in August 2025 is absent from the February 2026 table and her current status is not in the record; and the chairman’s June 2025 departure was never announced in a current report, leaving four months of interim chairmanship, with neither its reason nor the value of the vesting acceleration disclosed.
• The patent window is short against the launch window. Issued patents expire between 2029 and 2035 against a possible 2027 launch; the stated protection beyond them is QIDP’s five-year non-patent extension plus three years under §505(b)(2).
• Manufacturing sits on one leased site with no disclosed inspection — a single ~22,000 square foot sterile facility in Petach Tikva, no third-party contract manufacturer, and no FDA pre-approval inspection in the record. Israel Innovation Authority rules also bind the deal through “restrictions on the transfer of know-how developed with IIA support outside of Israel”, and the IIA liability and redemption amounts are not in the record.
• Nothing commercial is quantified. No list price, no gross-to-net assumption and no revenue, expense or capital-expenditure guidance has ever been given; the only forward financial guidance in the company’s history is cash runway, revised repeatedly. Reimbursement rests on a belief that launch is supportable “under existing Medicare rates”, and no New Technology Add-on Payment application has been filed or granted.
• Several items a reader would check are simply missing: the SHIELD II interim efficacy numbers; the content of the 2023 protocol amendment and the reason for the pause before it; any Special Protocol Assessment or orphan designation; remaining capacity under the $200 million primary shelf — a public float worth about $39.4 million on the 7.33 million market-data float at the $5.37 close, a calculation, sits below the $75 million threshold at which a Form F-3 issuer’s primary capacity is limited, and no filing discusses whether that limitation applies; any share count or headcount after June 30 and December 31, 2025; and a Nasdaq letter confirming the November 2024 stockholders’-equity deficiency was cured — equity is now $5,388 thousand against a $2,500,000 threshold with a $15.6 million half-year loss behind it.
• And housekeeping errors in the company’s own documents: a warrant tranche issued in August 2024 labelled “April 2022”; the Nasdaq equity rule cited as 5450(b)(1), a Global Market standard, by a Capital Market issuer; grant receipts of $4,888 thousand and then $4,898 thousand while the note says no new payments arrived; a purchase agreement dated December 23 in the exhibits and December 26 in two later filings; and 232,920 warrants cancelled in March 2026 “due to non-compliance with one of the terms of the Inducement Letter”, a term the filings never identify.

What to watch, in order

1. October 28, 2026. The virtual Investor Day, where management plans to outline its “PolyPid 2030” strategy, update on D-PLEX and introduce PD01B for diabetic foot infections.
2. November 28, 2026. Everything else here is downstream of it, and the decision is not forecastable from anything in the record.
3. Whether an advisory committee is announced before then. None is scheduled and none has been ruled out. An announcement at this stage would be new information in either direction, and the absence of one through November is itself information.
4. Whether a pre-approval inspection of the Petach Tikva site surfaces. One sterile facility, no contract manufacturer, and no FDA inspection disclosed in any filing.
5. Whether a European partner is announced. A signed agreement would replace up to €110 million of milestone structure that left with the old one; silence through the European review leaves the largest market outside North America unpartnered.
6. Confirmation that the $15.0 million milestone was actually received. It was earned on July 27 and was expected in September 2026, and it falls after the last reported balance-sheet date, so the first financial statement to show it is the FY2026 annual report.
7. Whether the going-concern language changes in that annual report. It has been present in the auditor’s report and in every set of notes to date, including the set filed the same day as a press release promising funding “into 2028.”
8. The first share count after 20,311,766, and whether the at-the-market facility kept selling. 796,581 shares for $3,703 thousand net went through it in the first half of 2026 and 153,140 for $780 thousand net in July; nothing after that is disclosed, and remaining capacity under the $200 million shelf is nowhere stated.
9. The $4.50 warrant block into June 2027. 7,289,644 warrants, roughly $32.8 million of proceeds and about 35 per cent of dilution if exercised in full. Two earlier tranches expired worthless because their milestone triggers never fired.
10. Any open-market purchase by any insider. There has not been one in the entire record, through a positive pivotal readout, a commercialisation agreement and a Priority Review grant.
11. Whether the redacted partner economics ever become visible. The Applicable Percentage, milestones (iii) to (ix) and both termination clauses are the difference between a described deal and a readable one.
12. Whether the chief medical officer question is ever answered, and whether a commercial officer is appointed ahead of a stated first-quarter launch.
13. The float and the volume into the date. 7.33 million shares freely trading on three-month average volume of 192,730, with 63.91 per cent of the count held by insiders and affiliates. Those are the figures to have in front of you on November 28; no forecast of what they produce is made here.
14. The short-interest series. The September 30 settlement is due around October 9; the position has been running at 0.64 per cent of the count and 1.78 per cent of the float.

Merlintrader bottom line

The useful way to read PolyPid is that the regulatory half of the story has arrived and the corporate half has not, and both converge on one date. SHIELD II hit: the primary endpoint ran 10.9 per cent against 18.1 per cent in the 798-patient population with incisions over 20 cm, a risk difference of −7.2 at p=0.0039, the key secondary on infection alone 3.8 per cent against 9.5 per cent at p=0.0013, all key secondaries met, and “no difference in serious treatment-emergent adverse events” between arms. The application was accepted for filing on July 27, 2026 with Priority Review and no filing review issues identified, giving a November 28, 2026 goal date a full quarter ahead of the company’s own earlier guidance. In Europe it was submitted September 14 and validated October 1 — validation being a completeness check that starts the clock, not an approval, with no opinion date in the record.

Underneath that sits a structural fact worth more attention than it usually gets. The predecessor Phase 3 in the same indication missed its primary endpoint at p=0.152, and the pre-specified large-incision subgroup that salvaged it — 423 subjects, a 54 per cent reduction, p=0.0032 — became the primary analysis population of the trial now under review. That is not a defect — the agency agreed the design and agreed a single pivotal study could support approval. It does mean the case rests on one confirmatory read of one subgroup hypothesis, and that the trial that missed has been removed from the most recent annual report rather than carried alongside the one that hit.

The balance sheet is where the asymmetry lives. $6,563 thousand of cash at June 30, 2026 against $13,835 thousand of operating cash use in that half-year; $5,388 thousand of shareholders’ equity; $317,077 thousand of accumulated deficit; zero revenue in every period in the company’s history; and substantial-doubt language in the auditor’s report and in both the annual and interim notes. Against that, genuinely improved: interest-bearing debt is zero since the loan was repaid on May 4, 2026, and $30.0 million has been contracted from the United States and Canadian partner — $15.0 million on execution, $15.0 million on filing acceptance — with over $290 million of further milestones stated. But the recurring payment clause is a redacted share of net profits, not the “tiered royalties” of the press release.

On the register, this is a company owned by the people who funded it. Every holder above five per cent is a private-placement counterparty, two of the eight directors work for two of the four largest, a board seat was expressly contemplated by a financing, and a large part of what the filings call ownership is warrant exposure struck at $4.50 and expiring in June 2027, behind 9.99 per cent blockers and 2,828,319 abeyance shares. The count has gone up 4.2 times in twenty-nine months and no insider has ever bought a share on the open market. Market data as of October 2, 2026 put the consequence in one figure: a float of 7.33 million shares out of 20.31 million, insider ownership at 63.91 per cent, institutional ownership at 17.07 per cent, and short interest at 1.78 per cent of that float on three-month average volume of 192,730. Those are market-data figures, labelled as such, and they sit on a different base from the company’s own 3.6 per cent for directors and executive officers — the filing counts the people who run the company, the market-data source counts everything not freely trading.

And then Europe, which changed shape two weeks after the application was filed there. The 2022 ADVANZ agreement was terminated by mutual agreement on October 1, 2026 and the rights reverted to PolyPid. What left with it is specific: up to €23 million of development milestones, up to €87 million of commercial milestones, a partner carrying minimum sales obligations after authorisation, and whatever the $2,548 thousand of deferred revenue becomes now the performance obligation cannot be satisfied. No consideration either way is disclosed, and the company’s stated response is an invitation rather than a process, with no adviser named and no approach disclosed.

Which leaves a short list of questions, none of which needs a view on surgical infection. What does the FDA do on November 28? Does a European partner appear before the CHMP opinion, or after it, or not at all? Does the FY2026 annual report still carry substantial doubt, and does it show the $15.0 million received? And do the $4.50 warrants get exercised into a positive decision or expire in June 2027 like the two tranches before them? They are in the money at the October 1, 2026 close, against a $5.37 close on October 1, 2026 and a market value of $109.07 million; the same market-data source shows a consensus price target of $11.75, an aggregate shown for reference only and not used in this analysis. Four answers, in documents and decisions due within months. Worth holding in view too is what the record does not let anyone check in the meantime: no reviewed quarterly financial statements, no published vote count, and eleven of the last eighteen months with no insider transaction record at all. The thinness is lawful, and it is still thinness.

None of the above is a recommendation, a target, or a view on the share price. It is a description of what is documented, what is guided, what is calculated and labelled as such, and what the record does not say.